Synapse - Clinical Pharmacy Specialists

Results (297)

Outpatient vs inpatient HiDA consolidation for AML: The MSKCC experience

Meeting Abstract

Boussi, L.; Burton, H.; Derkach, A.; Nemirovsky, D.; Ciervo, J.; Tallman, M. S.; Stein, E. M.; Cai, S.
Blood (2024)

Efficacy of budesonide monotherapy for low grade GI GVHD after post transplant cyclophosphamide

Meeting Abstract

Cook, M.; Vadakkel, G.; Chinapen, S.; Perales, M. A.; Tamari, R.; Papadopoulos, E. B.; Ponce, D. M.; Shaffer, B. C.; Lin, A.
Blood (2024)

Fulltext@MSK | Save

Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors

Meeting Abstract

Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Defining the rates of cytokine release syndrome associated with talquetamab step-up doses

Meeting Abstract

Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
Blood (2024)

Fulltext@MSK | Save

Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma

Meeting Abstract

Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
Blood (2024)

Fulltext@MSK | Save

Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma

Meeting Abstract

Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
Blood (2024)

Fulltext@MSK | Save

Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma

Meeting Abstract

Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
Blood (2024)

Fulltext@MSK | Save

Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction

Meeting Abstract

Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
Blood (2024)

Fulltext@MSK | Save

How a self-assessment mobile app for cancer treatment facilities became a tool for successful collaborations with Ministries of Health and NGOs

Meeting Abstract

Swindell, J.; Nwokwu, U.; Dr, K. A.; Koranteng, L.; O'Brien, D. M.
International Journal of Cancer (2024)

Fulltext@MSK | Save

Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)

Meeting Abstract

Scordo, M.; Perales, M. A.; Mauguen, A.; Lin, A.; Kunvarjee, B.; Bieler, J.; Nguyen, L. K.; Paes Pena, M.; Cho, C.; Gyurkocza, B.; more...
Bone Marrow Transplantation (2024)

Fulltext@MSK | Save